An interventional study of Laparoscopic Ultrasound-Guided Myomectomy and Conventional Laparoscopic Myomectomy in Uterine Fibroids (Leiomyoma), sponsored by Hua Li. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Hua Li · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.
Among the 40 studies in Leiomyoma with a site in China, this one is the 17th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 22 of the 22 other live ones, and was the 40th registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Peking University Aerospace Center Hospital · Sites in China
Women only
Shenzhen Kangzhe Biotechnology Co., Ltd. · Sites in China
Ages 18–50 · Women only
Zhejiang University · Sites in China
Ages 18–65 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 20 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 3
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 66 across 307 interventional studies indexed under Leiomyoma.
Median enrollment 120 across the 29 interventional studies, 200 across the 11 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 40 have an industry lead sponsor. The 10 most frequent:
Hua Li is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Hua Li has 1 study filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Leiomyoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06828419Second Affiliated Hospital of Wenzhou Medical UniversityA Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT05840042Wenwen WangEpidemiology and Risk Factors of Uterine Fibroids in China | 2026-12-31 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Leiomyoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.
The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.
The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.
Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.
Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.
Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.
Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal.
Procedure: Laparoscopic Ultrasound-Guided Myomectomy
Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance.
Procedure: Conventional Laparoscopic Myomectomy
During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety.
Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety.
Fibroid Removal Rate
For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100.
Time frame: During surgery and within 3 months after surgery
Residual Uterine Fibroid Rate
Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100.
Time frame: 3 months after surgery (+/- 14 days)
Difference Between Removed and Preoperatively Identified Fibroid Counts
For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging.
Time frame: Preoperative assessment and during surgery
Operative Time
Duration of the surgical procedure, measured in minutes.
Time frame: During surgery
Estimated Intraoperative Blood Loss
Estimated volume of blood lost during surgery, measured in milliliters.
Time frame: During surgery
Participants With Intraoperative Complications
Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury.
Time frame: During surgery
Participants With Postoperative Complications
Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits.
Time frame: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
Postoperative Length of Hospital Stay
Time from completion of surgery to hospital discharge, measured in days.
Time frame: Perioperative
Postoperative Pain Score
Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain.
Time frame: 2 and 6 hours after surgery
Time to First Postoperative Ambulation
Time from completion of surgery to first postoperative ambulation, measured in hours.
Time frame: Perioperative
Time to First Postoperative Flatus
Time from completion of surgery to first passage of flatus, measured in hours.
Time frame: Perioperative
Duration of Postoperative Uterotonic Treatment
Duration of postoperative uterotonic medication use, measured in hours.
Time frame: Perioperative
Time to Postoperative Drain Removal
Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed.
Time frame: Perioperative
Participants With Postoperative Urinary Dysfunction
Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit.
Time frame: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Participants With Postoperative Bowel Dysfunction
Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit.
Time frame: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Change From Baseline in Female Sexual Function Index Score
Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.
Time frame: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Oswestry Disability Index Score
Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability.
Time frame: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Zung Self-Rating Anxiety Scale Score
Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety.
Time frame: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
15-Item Quality of Recovery Questionnaire Score
Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated.
Time frame: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
Plan to share: No — There is no plan to share de-identified individual participant data with researchers outside the study team.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.
Of 53 non-industry interventional studies with no phase under Leiomyoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 26 months is below that.
Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 15 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hua Li